Novartis Venture Fund
Novartis's corporate venture fund, run from Basel and Cambridge, Massachusetts. It makes seed and Series A investments in biotech companies, including cancer drug developers such as Artios Pharma, CatalYm and Epsilogen.
Overview
The Novartis Venture Fund 'was created to foster innovation, drive significant patient benefit, and generate superior returns by nurturing and investing in innovative life science companies'. Its site states 'We manage over USD 750 million in committed capital and more than 40 portfolio companies across North America and Europe', operating 'from our offices in Basel, Switzerland and Cambridge, MA, USA', and that it specialises 'in investments ranging from USD 5-10 million, primarily focusing on Seed and Series A stage companies'. Its portfolio page lists more than 30 companies. Oncology-relevant names include Artios Pharma (DNA damage response), Amphista Therapeutics (targeted protein degradation), CatalYm (anti-GDF-15 immunotherapy), Epsilogen (IgE antibodies for cancer), Fore Biotherapeutics and Tagworks Pharmaceuticals (click-chemistry antibody-drug conjugates).
Portfolio in OnCo (0)
Filter the startups tableNo OnCo company names this investor yet. Portfolio links are declared on the startup record (`investors`), so adding one there lists it here.
Notes
top- Founding year not stated; omitted. The portfolio page gives names without descriptions, so oncology focus of the named companies is from general knowledge.